Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The university’s $17.9 billion endowment has also invested directly in OpenAI and in OpenAI’s corporate venture fund, documents show.
(Bloomberg) -- Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush.Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsBonds Retreat as Doubts Over Rate Cuts Creep In: Markets WrapBitcoin Surges Past $42,000 as Crypto Rally Gathers SteamHere’s How to Invest in Gold as It Hits an All-Time HighAlaska Air Agrees to Buy Hawaiian in $1.9 Billion D
Though Carmot’s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Wegovy and Eli Lilly & Co.’s Zepbound.
Bloomberg Swiss drugmaker Roche agreed to pay as much as US$3.1 billion (HK$24.1 billion) for US weight-loss treatment developer Carmot Ther...